Items Tagged ‘UNM CC Features’

February 28th, 2014

No Significant Bone Density Differences Between Aromasin and Arimidex

By

The Society of Surgical Oncology and the American Society for Radiation Oncology have announced new surgical guidelines indicating that although negative margins (no ink on tumor) reduce the risk of local recurrence, wider margin widths do not significantly lower this risk—and the routine practice of removing larger amounts of healthy breast tissue beyond the edge […]

View full entry

Tags: UNM CC Features


November 25th, 2013

Kyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed Multiple Myeloma

By

The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple myeloma, according to the results of a study published in Blood. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of […]

View full entry

Tags: UNM CC Features


November 18th, 2013

Panobinostat Plus Velcade and Dexamethasone Shows Promise in Heavily Pretreated Myeloma

By

The experimental drug panobinostat (LBH-589) in combination with Velcade® (bortezomib) and dexamethasone is effective for heavily pretreated multiple myeloma, according to the final results from a phase 2 clinical trial published in Blood. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the […]

View full entry

Tags: UNM CC Features


June 11th, 2013

Gene Mutations Common In African American Women with Triple-Negative or Early Onset Breast Cancer

By

Among African-American women with breast cancer referred for genetic counseling, one in five had an inherited mutation in at least one of the 18 genes that are linked with breast cancer susceptibility. The frequency of gene mutations was even higher in certain subgroups of these women. These results were presented at the 2013 Annual Meeting […]

View full entry

Tags: UNM CC Features


June 10th, 2013

Avastin Improves Outcomes for Women with Advanced Cervical Cancer

By

In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Each year in the United States, more than 12,000 women are diagnosed with cervical cancer and […]

View full entry

Tags: UNM CC Features


August 30th, 2012

Hollywood's Stars Illuminate Stand Up to Cancer's Nationally Televised Fundraising Event September 7

By

AUGUST 22, 2012 (Los Angeles / New York) – Stand Up To Cancer (SU2C) is proud to announce the Hollywood community is once again rallying together and lending its support to the third SU2C primetime television fundraising special on Friday, Sept. 7 (8:00-9:00 PM ET /PT). Gwyneth Paltrow, Julia Roberts, Matt Damon, Michael Douglas, Jessica […]

View full entry

Tags: UNM CC Features


February 10th, 2012

Older Postmenopausal Women More Likely to Die From Breast Cancer

By

Among postmenopausal women with hormone receptor-positive breast cancer, the likelihood of dying from breast cancer increases with age. These results were published in the Journal of the American Medical Association. Of the more than 200,000 cases of breast cancer diagnosed each year in theUnited States, roughly 40 percent occur in women over the age of […]

View full entry

Tags: UNM CC Features


January 20th, 2012

Oncotype DX Colon Cancer Test Changes Treatment in One-Third of Patients

By

A survey of oncologists suggests that the Oncotype DX colon cancer test changes treatment recommendations for roughly one-third of patients with Stage II colon cancer. These results will be presented at the 2012 Gastrointestinal Cancers Symposium. Gene expression profiling explores the patterns of genes that are active in tumor cells. Studies suggest that gene expression […]

View full entry

Tags: UNM CC Features


October 26th, 2011

CancerConnect Live Web Chat with Dr. Howard Hochster on Advances in Treatment Decision Making for Patients with Early-Stage Colon Cancer on Tuesday, November 8, 2011 at 6:00 PM Eastern Time

By

Advances in Treatment Decision Making for Patients with Early-Stage Colon Cancer- Live Web Chat with Howard Hochster, MD Dr. Howard Hochster is a Professor of Medicine at Yale School of Medicine (Medical Oncology), the Associate Cancer Center Director for Clinical Research at Yale Cancer Center and the Director of the GI Oncology Program. Click here for […]

View full entry

Tags: UNM CC Features


July 29th, 2011

Micrometastases in Sentinel Node Don’t Worsen Breast Cancer Survival

By

Detection of very small areas of cancer (micrometastases) in the sentinel lymph node through use of highly sensitive testing is not associated with breast cancer outcomes. These results were published in the Journal of the American Medical Association. For women with early breast cancer, determining whether the cancer has spread to the axillary (under the […]

View full entry

Tags: UNM CC Features


July 27th, 2011

CancerConnect Live Web-Chat with Dr Gutin on Gliomas and Surgery for Brain Cancer Today at 6:00 PM Eastern Time on

By

Cancer Connect Features Memorial Sloan-Kettering Cancer Center Expert Discussing Surgical Management of Brain Cancers Ketchum/Sun Valley, Idaho–CancerConnect, announces the first in its series of Live Chats with the Experts, beginning on Wednesday, July 27 at 6PM Eastern Time.  This premier program features Philip Gutin, MD, Chair of Neurosurgery at Memorial Sloan-Kettering Cancer Center. Featured recently as […]

View full entry

Tags: UNM CC Features


July 27th, 2011

Tarceva Outperforms Chemotherapy for Initial Treatment of Lung Cancer with an Mutation

By

Among patients with advanced non-small cell lung cancer that tests positive for a mutation in the EGFR gene, initial treatment with the targeted therapy Tarceva® (erlotinib) produces better outcomes and fewer serious side effects than chemotherapy.  These results were published in Lancet Oncology. Lung cancer remains the leading cause of cancer death in the United […]

View full entry

Tags: UNM CC Features


June 8th, 2011

Identifies Stage II Colon Cancer with Higher Risk of Recurrence

By

Among patients with Stage II colon cancer, the Oncotype DX colon cancer test provides information about the risk of cancer recurrence and may help guide treatment decisions. These results were presented at the 2011 annual meeting of the American Society of Clinical Oncology. Gene expression profiling explores the patterns of genes that are active in tumor […]

View full entry

Tags: UNM CC Features


June 8th, 2011

Onco DX Identifies Stage II Colon Cancer with Higher Risk of Recurrence

By

Among patients with Stage II colon cancer, the Oncotype DX® colon cancer test provides information about the risk of cancer recurrence and may help guide treatment decisions. These results were presented at the 2011 annual meeting of the American Society of Clinical Oncology. Gene expression profiling explores the patterns of genes that are active in tumor […]

View full entry

Tags: UNM CC Features


April 12th, 2011

Study Enrolling Women with HER2-positive, Advanced Breast Cancer

By

The Phase III EMILIA trial is enrolling women with previously treated, HER2-positive, locally advanced or metastatic breast cancer. The study is evaluating an investigational drug known as trastuzumab emtansine (T-DM1). T-DM1 links the HER2-targeted drug Herceptin® (trastuzumab) with a chemotherapy drug (DM1). T-DM1 delivers Herceptin and DM1 directly to HER2-positive cells. Approximately 20-25% of breast […]

View full entry

Tags: UNM CC Features